Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

OBXObsidian Therapeutics, Inc.Signing up patients

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Tumor Skin · Metastatic Melanoma · Melanoma · Lung Cancer · Metastatic Lung Cancer · Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
254 (planned)
Started
Oct 25, 2023
Main results expected
Jun 30, 2029
Fully finished
Jun 30, 2029
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Incidence and nature of dose-limiting toxicities (DLTs)

    Measured over: 28 Days

  • The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

    Measured over: 2 years

  • The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

    Measured over: 2 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT06060613 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06060613) ↗